GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Nanexa AB (OSTO:NANEXA) » Definitions » EBIT

Nanexa AB (OSTO:NANEXA) EBIT : kr-64.26 Mil (TTM As of Sep. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Nanexa AB EBIT?

Nanexa AB's earnings before interest and taxes (EBIT) for the three months ended in Sep. 2024 was kr-4.35 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Sep. 2024 was kr-64.26 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Nanexa AB's annualized ROC % for the quarter that ended in Sep. 2024 was -21.84%. Nanexa AB's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2024 was -137.20%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Nanexa AB's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2024 was -20.81%.


Nanexa AB EBIT Historical Data

The historical data trend for Nanexa AB's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nanexa AB EBIT Chart

Nanexa AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -12.71 -21.49 -35.82 -57.97 -76.02

Nanexa AB Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -6.38 -51.25 -2.73 -5.93 -4.35

Competitive Comparison of Nanexa AB's EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Nanexa AB's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nanexa AB's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Nanexa AB's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Nanexa AB's EV-to-EBIT falls into.



Nanexa AB EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-64.26 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Nanexa AB  (OSTO:NANEXA) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Nanexa AB's annualized ROC % for the quarter that ended in Sep. 2024 is calculated as:

ROC % (Q: Sep. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2024 ) + Invested Capital (Q: Sep. 2024 ))/ count )
=-18.2 * ( 1 - 0.63% )/( (83.58 + 82.057)/ 2 )
=-18.08534/82.8185
=-21.84 %

where

Note: The Operating Income data used here is four times the quarterly (Sep. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Nanexa AB's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Sep. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2024  Q: Sep. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-17.412/( ( (13.015 + max(-16.992, 0)) + (12.366 + max(-11.938, 0)) )/ 2 )
=-17.412/( ( 13.015 + 12.366 )/ 2 )
=-17.412/12.6905
=-137.20 %

where Working Capital is:

Working Capital(Q: Jun. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(8.364 + 0.118 + 0) - (6.548 + 0 + 18.926)
=-16.992

Working Capital(Q: Sep. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(6.74 + 0.117 + 0) - (4.346 + 0 + 14.449)
=-11.938

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Sep. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Nanexa AB's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Sep. 2024 )
=-64.264/308.763
=-20.81 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Nanexa AB EBIT Related Terms

Thank you for viewing the detailed overview of Nanexa AB's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Nanexa AB Business Description

Traded in Other Exchanges
Address
Virdings Alle 32B, Uppsala, SWE, 75450
Nanexa AB is a pharmaceutical company developing injectable drug products based on the proprietary drug delivery system PharmaShell - the high drug load delivery system enabling the next generation long-acting injectables through atomic layer precision. The company develops its products and also has collaboration agreements with several pharma companies, among others AstraZeneca. Geographically, the company derives maximum revenue from Nordic countries.

Nanexa AB Headlines

No Headlines